Cetuximab, received full FDA approval for the treatment of patients with K-RAS wild-type, EGFR-mutant HNSCC following reports that its addition to radiation therapy results in significant improvements in disease control and overall survival (96, 97). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.